MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1186/s11658-026-00859-2

Медицинская библиотека · Cellular & molecular biology letters · 2026

TSP50 attenuates metabolic dysfunction-associated steatotic liver disease via SCD1 degradation-mediated suppression of hepatocyte lipogenesis.

Liang Jiujia, Luan Zhihui, Jin Rong, Su Rina, Ge Jiarong, Tian Xiao, Niu Chunxue, Li Jiawei, Li Xiaoli, Gao Feng, Song Zhenbo, Sun Luguo, Wang Guannan, Zheng Lihua, Sun Ying, Liu Lei, Bao Yongli, Wang Shuyue, Yang Xiaoguang

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a major contributor to chronic liver disease worldwide, yet the molecular mechanisms driving its pathogenesis remain incompletely defined. Although dysregulated hepatic lipogenesis is a well-established driver of MASLD progression, the role of testes-specific protease 50 (TSP50)—an enzyme with demonstrated oncogenic functions in multiple cancers—in hepatic lipid metabolism and its potential involvement in the development of MASLD remains unexplored.

METHODS

The study utilized the STelic Animal Model (STAM) along with high-fat/high-cholesterol plus fructose (HFF) and methionine-choline deficient (HFMCD) dietary models to evaluate the functional role of TSP50 in MASLD progression. Hepatocyte-specific knockout and AAV-mediated TSP50 reconstitution were performed to assess cell-autonomous effects. Mechanistic insights were gained through biochemical analyses of lipid metabolism pathways and protein interaction studies.

RESULTS

TSP50 deficiency markedly accelerated MASLD progression across all experimental models, promoting hepatic steatosis, inflammation and fibrosis while increasing susceptibility to hepatocellular carcinoma (HCC). Conversely, TSP50 supplementation exerted protective effects against MASLD development. Furthermore, we identified a novel regulatory mechanism whereby TSP50 directly interacts with and degrades stearoyl-CoA desaturase 1 (SCD1) through its catalytic hydrolase activity, thereby suppressing de novo lipogenesis. The inhibitor of SCD1 rescued hepatic TSP50 knockout induced lipid accumulation and liver injury during MASLD.

CONCLUSIONS

Our study reveals the role of TSP50 in hepatic lipid metabolism, identifying it as a novel regulator of hepatic de novo lipogenesis that exerts protective effects against MASLD through catalytic degradation of SCD1. These findings not only advance our understanding of MASLD pathogenesis but also offer novel insights for developing therapeutic strategies.

Для цитирования: Liang Jiujia, Luan Zhihui, Jin Rong, Su Rina, Ge Jiarong, Tian Xiao, Niu Chunxue, Li Jiawei, Li Xiaoli, Gao Feng, Song Zhenbo, Sun Luguo, Wang Guannan, Zheng Lihua, Sun Ying, Liu Lei, Bao Yongli, Wang Shuyue, Yang Xiaoguang. TSP50 attenuates metabolic dysfunction-associated steatotic liver disease via SCD1 degradation-mediated suppression of hepatocyte lipogenesis.. Cellular & molecular biology letters. 2026. DOI: 10.1186/s11658-026-00859-2.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.